ArticleApplied immunohistochemistry & molecular morphology : AIMM2026
Diagnostic Utility of T-PIT, PIT-1, and SF-1 in Differentiating Pituitary Neuroendocrine Tumors From Sinonasal and Skull Base Tumors.
Article in Applied immunohistochemistry & molecular morphology : AIMM, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pituitary adenoma (pituitary neuroendocrine tumor) can present a diagnostic pitfall when it involves the sinonasal tract ectopically or by direct extension due to morphologic and immunohistochemical overlap with sinonasal small round blue cell tumors. T-box transcription factor (T-PIT), pituitary-specific transcription factor (PIT-1), and steroidogenic factor 1 (SF-1) have emerged as lineage-specific markers for corticotroph, somatotroph, and gonadotroph-type adenomas, respectively, but have not been extensively tested in sinonasal tumors. We examined T-PIT, PIT-1, and SF-1 expression across sinonasal and skull base tumors to assess their specificity in this differential diagnosis. Staining for T-PIT, PIT-1, and SF-1 was performed on tissue microarrays including 199 sinonasal tumors and 12 nonsinonasal head and neck neuroendocrine carcinomas. Whole tissue sections from 20 adenomas, 2 olfactory carcinomas, and 1 Merkel cell carcinoma of nasal skin also underwent staining for all 3 markers, while 9 other sinonasal or skull base tumors underwent staining for T-PIT and PIT-1 only. All 223 sinonasal tumors and neuroendocrine carcinomas of the head and neck were negative for T-PIT and PIT-1. Only 7 of 214 nonpituitary tumors (3.3%) showed SF-1 expression, including 2 of 43 HPV-positive squamous cell carcinomas, 1 of 75 HPV-negative squamous cell carcinomas, 2 of 8 SMARCB1-deficient sinonasal carcinomas, 1 of 4 salivary neuroendocrine carcinomas, and 1 of 5 NUT carcinomas. All pituitary tumors stained as expected. These findings demonstrate that T-PIT and PIT-1 are highly specific for pituitary origin, while SF-1 shows limited off-target expression in certain high-grade sinonasal tumors with chromatin remodeling (e.g., NUT carcinoma and SMARCB1-deficient carcinoma).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.